Discover the integrative oncology potential of fenbendazole—a veterinary antiparasitic now under investigation for anticancer use. This course, led by Dr. Nathan Goodyear, examines fenbendazole’s impact on cancer cell metabolism, microtubule function, immune activation, and apoptosis. Participants will explore its pharmacology, off-label use in humans, safety profile, and synergy with metabolic therapies. Through clinical context and current evidence, practitioners will gain insight into how fenbendazole may complement comprehensive cancer protocols targeting multiple hallmarks of cancer.